1. Purification of Human CD34+CD90+ HSCs Reduces Target Cell Population and Improves Lentiviral Transduction for Gene Therapy
- Author
-
Stefan Radtke, Dnyanada Pande, Margaret Cui, Anai M. Perez, Yan-Yi Chan, Mark Enstrom, Stefanie Schmuck, Andrew Berger, Tom Eunson, Jennifer E. Adair, and Hans-Peter Kiem
- Subjects
Hematopoietic Stem Cells ,Gene Therapy ,CD90 CD34 ,Lentivirus Transduction ,Stem Cell Enrichment / Cell Sorting ,single cell RNA sequencing ,Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
Hematopoietic stem cell (HSC) gene therapy has the potential to cure many genetic, malignant, and infectious diseases. We have shown in a nonhuman primate gene therapy and transplantation model that the CD34+CD90+ cell fraction was exclusively responsible for multilineage engraftment and hematopoietic reconstitution. In this study, we show the translational potential of this HSC-enriched CD34 subset for lentivirus-mediated gene therapy. Alternative HSC enrichment strategies include the purification of CD133+ cells or CD38low/– subsets of CD34+ cells from human blood products. We directly compared these strategies to the isolation of CD90+ cells using a good manufacturing practice (GMP) grade flow-sorting protocol with clinical applicability. We show that CD90+ cell selection results in about 30-fold fewer target cells in comparison to CD133+ or CD38low/– CD34+ hematopoietic stem and progenitor cell (HSPC) subsets without compromising the engraftment potential in vivo. Single-cell RNA sequencing confirmed nearly complete depletion of lineage-committed progenitor cells in CD90+ fractions compared to alternative selections. Importantly, lentiviral transduction efficiency in purified CD90+ cells resulted in up to 3-fold higher levels of engrafted gene-modified blood cells. These studies should have important implications for the manufacturing of patient-specific HSC gene therapy and gene-engineered cell products.
- Published
- 2020
- Full Text
- View/download PDF